Dalan Animal Health, Inc. Raised $1.9M for the Development of the First Ever Honeybee Vaccine

Dalan Animal Health, Inc., is a biotech company developing vaccines for new-age production animals. It raised $1.9M in seed funding to accelerate the company's development and commercial activities for the launch of a breakthrough honeybee vaccine.


Dalan's vaccine will be used against American Foulbrood, a highly contagious disease threatening beehives worldwide. The company successfully tested the safety and efficacy of its first product and is going to submit a license application for the conditional approval of the vaccine this soon.

Other underserved industries such as shrimp, mealworms and grasshoppers used in feed and food production are going to be the company's next target. This breakthrough vaccine development can prevent the annual losses due to diseases that are limiting growth across these billion-dollar industries.

At present the company is operating virtually, partnering with European and U.S laboratories. It is planning to transition into a fully integrated company over the coming 18 months. Dalan expects to raise a larger round of funding in 2022 to expand their commercial offering and further advance a pipeline of novel vaccines for other new production animals.

"It's very exciting to have the strong support of our investors on this innovative vaccine. This is not only innovation for animal health but an important step in saving bees and providing a more sustainable food supply" says Dalan's CEO Annette Kleiser.